EyePoint Pharmaceuticals Inc’s filing revealed that its 10% Owner Cormorant Asset Management, LP acquired Company’s shares for reported $10.08 million
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
EyePoint Pharmaceuticals Inc’s recent filing unveils that its 10% Owner Cormorant Asset Management, LP acquired Company’s shares for reported $10.49
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
EyePoint Pharmaceuticals Inc’s recent filing unveils that its 10% Owner Cormorant Asset Management, LP acquired Company’s shares for reported $10.49
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
EyePoint Pharmaceuticals Inc’s recently made public that its 10% Owner Cormorant Asset Management, LP acquired Company’s shares for reported $10.49
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
EyePoint Pharmaceuticals Inc’s recently made public that its SVP & Chief Commercial Officer Jones David Scott unloaded Company’s shares for
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. EyePoint Pharmaceuticals